-
Huntington’s Disease Therapeutics Conference 2026 – Day 3
Latest News
-
Improving Huntington's disease clinical trial recruitment through patient and family education
How can we improve recruitment into Huntington's disease clinical trials? Talking directly with families works!
-
Chubby mice reveal the importance of the hypothalamus in Huntington's disease
Huntington's disease mice are fat but HD patients lose weight – is a brain area called the hypothalamus to blame?
-
The genetic 'gray area' of Huntington's disease: what does it all mean?
Intermediate alleles and reduced penetrance – the genetic 'gray area' of Huntington’s disease, explained
-
Dimebon fails in late-stage human HD clinical trial
Dimebon fails to improve symptoms in HD patients in the HORIZON trial
-
FDA: further trial needed for Huntexil approval in HD
Bad news for Huntexil – the FDA requires another trial before it can be approved in the US
-
Successful gene therapy trial in Parkinson’s Disease gives hope for HD
Success for brain ‘gene therapy’ in Parkinson’s disease – good news for similar treatments being developed in HD
-
Gene silencing for HD: the story so far
Is gene silencing as exciting as it sounds for HD, and what might the future hold?
-
Interview: Graeme Bilbe, Global Head for Neuroscience at Novartis
HDBuzz interviews Graeme Bilbe, Global Head for Neuroscience at pharmaceutical giant Novartis, about their HD researc
-
What do sheep brains have to do with HD?
How smart are sheep, and why do HD researchers care?
-
Interview: CHDI Management
HDBuzz interviews three top scientists from CHDI, the biggest funder and driver of HD research worldwide
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
